A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

Oncotarget

Volumn 8, Issue 42, 2017, Pages 73144-73153

  Ocana, Alberto ^a   Gil Martin, Marta ^b   Martín, Miguel ^c   Rojo, Federico ^d   Antolín, Silvia ^e   Guerrero, Ángel ^f   Trigo, José Manuel ^g   Muñoz, Montse ^h   Pandiella, Atanasio ⁱ   Diego, Núria Gonzalo ^j   Bezares, Susana ^k   Caballero, Rosalía ^k   Carrasco, Eva ^k   Urruticoechea, Ander ^l  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Grupo de Trabajo Ecografía SoMaMFyC   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ UNIVERSITY OF SALAMANCA   (Spain)

^j HOSPITAL DURAN I REYNALS   (Spain)

^k GEICAM Spanish Breast Cancer Group ^*  (Spain)

^l Fundación Onkologikoa   (Spain)

more..

Author keywords

dasatinib; HER2 positive breast cancer; metastatic breast cancer; SRC kinase; trastuzumab resistance

Indexed keywords

EID: 85033554312     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17113     Document Type: Article

References (0)